Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372428 | 0.87 | KMT2A (0.58) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29625240 | 0.86 | NPC1 (0.61) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL24499496 | 0.86 | NPC1 (0.61) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1385665 | 0.86 | NPC1 (0.61) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1385664 | 0.86 | NPC1 (0.61) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6361162 | 0.85 | NPC1 (0.59) | ALDH1A1HTTNPC1RAB9AKMT2A | |
| SCHEMBL4079701 | 0.85 | SMN1; SMN2 (0.65) | ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL6290134 | 0.85 | NPC1 (0.59) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL30259909 | 0.85 | NPC1 (0.59) | ALDH1A1HTTNPC1RAB9AKMT2A | |
| SCHEMBL2636050 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5834514-A | INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-11-10 | — | — | US | claimed |
| EP-0758891-A4 | HALOMETHYL AMIDES AS IL-1-g(b) PROTEASE INHIBITORS | SANOFI WINTHROP INC (US) | 1997-12-03 | — | — | EP | claimed |
| EP-0758891-A1 | HALOMETHYL AMIDES AS IL-1$g(b) PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-02-26 | — | — | EP | claimed |
| WO-1995029672-A1 | HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-1806346-B1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5834514-A | INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0758891-A4 | HALOMETHYL AMIDES AS IL-1-g(b) PROTEASE INHIBITORS | SANOFI WINTHROP INC (US) | 1997-12-03 | — | — | EP | disclosed |
| EP-0758891-A1 | HALOMETHYL AMIDES AS IL-1$g(b) PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1995029672-A1 | HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-11-09 | — | — | WO | disclosed |
| US-4800211-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1989-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 245/4885HTT 2557/4885SMN1; SMN2 2385/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 281/4885HTT 2259/4885SMN1; SMN2 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.